NFE2L2

Also known as NRF2, HEBP1, nuclear factor, erythroid 2 like 2, IMDDHH, Nrf-2, NFE2 like bZIP transcription factor 2

Nuclear factor erythroid 2-related factor 2 (NRF2), also known as nuclear factor erythroid-derived 2-like 2, is a transcription factor that in humans is encoded by the NFE2L2 gene. NRF2 is a basic leucine zipper (bZIP) protein that may regulate the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation, according to preliminary research. In vitro, NRF2 binds to antioxidant response elements (AREs) in the promoter regions of genes encoding cytoprotective proteins. NRF2 induces the expression of heme oxygenase 1 in vitro leading to an increa

Gene data

NFE2L2

Name: NFE2 like bZIP transcription factor 2
Type: protein-coding
Position: 177,218,667–177,392,756 (−)
Aliases: IMDDHH, NRF2, Nrf-2
Ensembl: ENSG00000116044
RefSeq RNA: NM_001145412.3, NM_001145413.3, NM_001313900.1, NM_001313901.1, NM_001313902.2
RefSeq protein: NP_001138884.1, NP_001138885.1, NP_001300829.1, NP_001300830.1, NP_001300831.1

This gene encodes a transcription factor which is a member of a small family of basic leucine zipper (bZIP) proteins. The encoded transcription factor regulates genes which contain antioxidant response elements (ARE) in their promoters; many of these genes encode proteins involved in response to injury and inflammation which includes the production of free radicals. Multiple transcript variants encoding different isoforms have been characterized for this gene. [provided by RefSeq, Sep 2015].

Gene Ontology

Biological process

response to ischemia

~11 min read

Article

11 sections

Contents

Structure
Tissue distribution
Localization and function
Target genes
Clinical relevance
Disease association
Therapeutic
Interactions
See also
References
External links

NRF2 appears to participate in a complex regulatory network and performs a pleiotropic role in the regulation of metabolism, inflammation, autophagy, proteostasis, mitochondrial physiology, and immune responses. Several drugs that stimulate the NFE2L2 pathway are being studied for treatment of diseases that are caused by oxidative stress.